List of Approved Hepatitis C Drugs

Direct Acting Antivirals Demonstrating Cure Rates of As High as 99%

When the drug Sovaldi (sofosbuvir) was first introduced into the market in September 2014, it marked not only a sea change in how we treated chronic hepatitis C (HCV) infection, it made obsolete earlier generation medications which demonstrated no where near the efficacy of this newer direct acting antiviral (DAA). Among them, Vertex Pharmaceutical's Incivek (telapravir) and Merck's Victrelis (boceprevir), both of which were voluntarily discontinued in October 2014 and December 2015, respectively.

Following fast on Sovaldi's heels were six additional DAA molecules and a number of combination pills able to treat an ever-widening range of HCV genotypes—and with shorter treatment duration and far fewer side effects.

With cure rates well exceeding 95% in many cases, the only challenge now is how to effectively expand access to the 130-150 million people chronically infected with HCV worldwide (including 9% of the HIV-infected population believed to be co-infected with HCV).

The following DAAs are listed by order of their FDA approval dates:

1
Epclusa (sofosbuvir, velpatasvir)

Photo courtesy Gilead Sciences

Approved on June 28, 2016, Epclusa (sofosbuvir, velpastsvir) is a fixed dose combination drug able to treat all six major HCV genotypes. Appropriate for use in persons with cirrhosis, as well as those with decompensated cirrhosis, Epclusa is prescribed in a once daily dose for a period of 1-6 weeks.

More »

2
Zepatier (elbasvir, grazoprevir)

Courtesy Merck

Approved in January 2016, Zepatier (elbasvir, grazoprevir) is a fixed dose combination drug used to treat HCV genotypes 1 and 4 with or without cirrhosis. Zepatier is a single pill, all-in-one therapy that does not require co-administration with any other drug. Zepatier is taken once daily with or without food for a duration of 12-16 weeks depending on HCV genotype and treatment history.

More »

3
Daklinza (daclatasvir)

Courtesy: Bristol Myer Squibb

Approved in July 2015, Daklinza (daclatasvir) is a drug used in combination therapy to treat HCV genotype 3 infection. Daklinza was the first DAA able to treat genotype 3 without the use of either peginterferon or ribavirin. Daklinza is co-administered with Sovaldi (sofosbuvir) and taken once daily with our without food for a period of 12 weeks.

More »

4
Technivie (ombitasvir, paritaprevir, ritonavir)

Courtesy AbbVie

Approved  in July 2015, Technivie (ombitasvir, paritaprevir/ritonavir) is a fixed dose combination drug  used in combination therapy to treat HCV genotype 4 infection. The three agents that comprise Technivie are also bundled in the two-pill therapy, Viekira Pak. The recommended dosage is two tablets taken twice daily, co-administered with ribavirin, for a period of 12 weeks.

More »

5
Viekira Pak

Approved in December 2014, Viekira Pak is a co-packaged drug combination used to treat HCV genotype 1 with or without cirrhosis. The pack includes one fixed dose combination drug Technivie (ombitasvir, paritaprevir, ritonavir) co-packaged alongside the drug dasabuvir. The recommended dosage is two tablets of Technvie taken once daily with food and one tablet of dasabuvir taken twice daily with food. Treatment duration is from 12-24 weeks.

More »

6
Harvoni, (ledipasvir, sofosbuvir)

 Approved in October 2014, Harvoni (ledipasvir, sofosbuvir) is a fixed dose combination drug used to treat HCV genotype 1 with or without cirrhosis. It was the first, all-in-one DAA that didn't require co-administration with either peginterferon or ribavirin. The recommended dosage is one tablet daily, taken with or without food. Treatment duration is from 12-24 weeks.

More »

7
Sovaldi (sofosbuvir)

Sovalilarge.jpg
Courtesy Gilead Sciences

Approved in December 2013, Sovaldi (sofosbivir) is a novel nucleotide polymerase inhibitor-class drug used to treat HCV genotype 1, 2, 3 and 4. (The drug molecule sofosbuvir is also a component of the fixed dose combination drug Harvoni.) The recommended dosage is one tablet daily taken with or without food. Depending on genotype, ribavirin may be included in combination therapy. For genotype 3 infection, Sovaldi is co-administered with Daklinza (daclatasvir). Treatment duration is from 12-24 weeks.

More »

8
Olysio (simeprevir)

Olysio.jpg
Photo courtesy Janssen Pharmaceuticals

Approved in November 2013, Olysio (simeprevir) is a protease inhibitor-class drug used in combination therapy to treat HCV genotype 1 infection. Olysio is prescribed for use with the drugs peginterferon and ribavirin. The recommended dosage is one tablet taken daily with food. Treatment duration is from 24-36 weeks.

More »

Continue Reading